{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:25:51Z","timestamp":1776209151817,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate clinical results and long-term patient-reported outcome measures (PROMs) on quality of life in cervical cancer patients following radiochemotherapy (RCT) and brachytherapy (BT) as definitive treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Between 2003 and 2023, a\u00a0total of 132 patients with advanced cervical cancer were evaluated for possible treatment. Patients treated by postoperative RCT, palliative radiotherapy, and those treated for recurrent disease were excluded. Thus, 46\u00a0patients receiving standard RCT and BT as their curative treatment were included in this study. PROMs were assessed prospectively by patients\u2019 self-completion of the EORTC-QLQ-C30 and EORTC-QLQ-CX24 questionnaires.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five-year overall survival (OS), distant metastases-free survival (DMFS), and pelvic tumor-free survival rates (PTFS) were 53%, 54%, and 83%, respectively. A\u00a0significant impact on OS was seen for FIGO (International Federation of Gynecologic Oncology) stage (IIB\u2013IIIA: 79% vs. IIIB\u2013IVA: 33%, <jats:italic>p<\/jats:italic>\u202f=\u20090.015), for overall treatment time (OTT; 50\u201365\u00a0d: 64% vs. &gt;\u202f65\u00a0d: 38%, <jats:italic>p<\/jats:italic>\u202f=\u20090.004), and for rectal D<jats:sub>2cc<\/jats:sub> (\u2264\u202f73\u202fGy: 50% vs. &gt;\u202f73\u202fGy: 38%, <jats:italic>p<\/jats:italic>\u202f=\u20090.046). The identical parameters were significantly associated with DMFS (FIGO stage: <jats:italic>p<\/jats:italic>\u202f=\u20090.012, OTT: <jats:italic>p<\/jats:italic>\u202f=\u20090.008, D<jats:sub>2cc<\/jats:sub>: <jats:italic>p<\/jats:italic>\u202f=\u20090.024). No parameters with a\u00a0significant influence on PTFS were seen. In multivariate analysis, an impact of FIGO stage on OS (<jats:italic>p<\/jats:italic>\u202f=\u20090.05) and DMFS (<jats:italic>p<\/jats:italic>\u202f=\u20090.014) was detected, and of rectal D<jats:sub>2cc<\/jats:sub> on DMFS (<jats:italic>p<\/jats:italic>\u202f=\u20090.031). The overall QoL score was 63\/100. Cognitive function was the least impaired (84\/100), while role functioning was the worst (67\/100). On the symptom scale, insomnia (46\/100), fatigue (41\/100), dyspnea (32\/100), pain (26\/100), and financial difficulties (25\/100) were scored the worst. According to EORTC-QLQ-CX24, peripheral neuropathy (36\/100) and lymphedema (32\/100) occurred most frequently. Impaired sexual\/vaginal functioning (32\/100) and body image (22\/100) were also frequently recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In patients with advanced cervical cancer, a\u00a0combination of RCT and BT remains an excellent treatment option. In terms of patient-reported long-term quality of life, specific support is needed to alleviate symptoms including lymphedema, peripheral neuropathy, and impaired sexual activity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-023-02196-1","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T17:02:26Z","timestamp":1706720546000},"page":"706-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiochemotherapy and interstitial brachytherapy for cervical cancer: clinical results and patient-reported outcome measures"],"prefix":"10.1007","volume":"200","author":[{"given":"Johanna","family":"Alfrink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Zoche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luitpold","family":"Distel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1367-5536","authenticated-orcid":false,"given":"Gerhard G.","family":"Grabenbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"issue":"4","key":"2196_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4103\/jmh.JMH_40_17","volume":"8","author":"Z Rahman","year":"2017","unstructured":"Rahman\u00a0Z et\u00a0al (2017) Assessment of quality of life in treated patients of cancer cervix. J\u00a0Mid-life Health 8(4):183. https:\/\/doi.org\/10.4103\/jmh.JMH_40_17","journal-title":"J Mid-life Health"},{"key":"2196_CR2","doi-asserted-by":"publisher","first-page":"102311","DOI":"10.1016\/j.ctrv.2021.102311","volume":"102","author":"HHB Wenzel","year":"2022","unstructured":"Wenzel\u00a0HHB et\u00a0al (2022) Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis\u2014a review. Cancer Treat Rev 102:102311. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102311","journal-title":"Cancer Treat Rev"},{"key":"2196_CR3","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S46247","author":"M Kamrava","year":"2014","unstructured":"Kamrava\u00a0M, Banerjee\u00a0R (2014) Brachytherapy in the treatment of cervical cancer: a\u00a0review. Int J Womens Health. https:\/\/doi.org\/10.2147\/IJWH.S46247","journal-title":"Int J Womens Health"},{"issue":"1","key":"2196_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12874-016-0289-x","volume":"17","author":"C Tax","year":"2017","unstructured":"Tax\u00a0C et\u00a0al (2017) Measuring health-related quality of life in cervical cancer patients: a\u00a0systematic review of the most used questionnaires and their validity. BMC Med Res Methodol 17(1):15. https:\/\/doi.org\/10.1186\/s12874-016-0289-x","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2196_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.radonc.2005.11.014","volume":"78","author":"R P\u00f6tter","year":"2006","unstructured":"P\u00f6tter\u00a0R et\u00a0al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy\u20143D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78(1):67\u201377. https:\/\/doi.org\/10.1016\/j.radonc.2005.11.014","journal-title":"Radiother Oncol"},{"issue":"9","key":"2196_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00066-021-01887-x","volume":"198","author":"R Vojt\u00ed\u0161ek","year":"2022","unstructured":"Vojt\u00ed\u0161ek\u00a0R et\u00a0al (2022) Treatment outcomes of MRI-guided adaptive brachytherapy in patients with locally advanced cervical cancer: institutional experiences. Strahlenther Onkol 198(9):783\u2013791. https:\/\/doi.org\/10.1007\/s00066-021-01887-x","journal-title":"Strahlenther Onkol"},{"key":"2196_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ctro.2021.10.005","volume":"32","author":"M le Guyader","year":"2021","unstructured":"le Guyader\u00a0M et\u00a0al (2021) High-dose-rate brachytherapy boost for locally advanced cervical cancer: oncological outcome and toxicity analysis of 4 fractionation schemes. Clin Transl Radiat Oncol 32:15\u201323. https:\/\/doi.org\/10.1016\/j.ctro.2021.10.005","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"2196_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/ijc.IJC_428_17","volume":"55","author":"S Chopra","year":"2018","unstructured":"Chopra\u00a0S et\u00a0al (2018) Locally advanced cervical cancer: a\u00a0study of 5\u2011year outcomes. Indian J Cancer 55(1):45\u201349. https:\/\/doi.org\/10.4103\/ijc.IJC_428_17","journal-title":"Indian J Cancer"},{"issue":"2","key":"2196_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.21873\/cdp.10201","volume":"3","author":"V De Sanctis","year":"2023","unstructured":"De Sanctis\u00a0V et\u00a0al (2023) Clinical outcomes and toxicity of CT-guided high dose-rate brachytherapy in women with locally-advanced cervical cancer. Cancer Diagn Progn 3(2):194\u2013200. https:\/\/doi.org\/10.21873\/cdp.10201","journal-title":"Cancer Diagn Progn"},{"issue":"1","key":"2196_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijrobp.2020.08.044","volume":"109","author":"AS Vittrup","year":"2021","unstructured":"Vittrup\u00a0AS et\u00a0al (2021) Persistence of late substantial patient-reported symptoms (LAPERS) after radiochemotherapy including image guided adaptive brachytherapy for locally advanced cervical cancer: a\u00a0report from the EMBRACE study. Int J Radiat Oncol Biol Phys 109(1):161\u2013173. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.044","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"2196_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5114\/jcb.2022.118674","volume":"14","author":"Y-T Xiu","year":"2022","unstructured":"Xiu\u00a0Y\u2011T et\u00a0al (2022) Prognostic factors for IB2-IIIB cervical cancer patients treated by radiation therapy with high-dose-rate brachytherapy in a\u00a0single-institution study. jcb 14(4):332\u2013340. https:\/\/doi.org\/10.5114\/jcb.2022.118674","journal-title":"jcb"},{"issue":"2","key":"2196_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/ijerph20021161","volume":"20","author":"Y Wang","year":"2023","unstructured":"Wang\u00a0Y et\u00a0al (2023) Long-term efficacy and toxicity of intensity-modulated radiotherapy in bulky cervical cancer. Int J Environ Res Public Health 20(2):1161. https:\/\/doi.org\/10.3390\/ijerph20021161","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"2196_CR13","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.7150\/jca.23974","volume":"9","author":"Y-Z Dang","year":"2018","unstructured":"Dang\u00a0Y\u2011Z et\u00a0al (2018) The efficacy and late toxicities of computed tomography-based brachytherapy with Intracavitary and interstitial technique in advanced cervical cancer. J\u00a0Cancer 9(9):1635\u20131641. https:\/\/doi.org\/10.7150\/jca.23974","journal-title":"J Cancer"},{"issue":"1","key":"2196_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.30773\/pi.2020.0286","volume":"18","author":"KH Seol","year":"2021","unstructured":"Seol\u00a0KH et\u00a0al (2021) Factors associated with the quality of life of patients with cancer undergoing radiotherapy. Psychiatry Investig 18(1):80\u201387. https:\/\/doi.org\/10.30773\/pi.2020.0286","journal-title":"Psychiatry Investig"},{"key":"2196_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12905-022-02003-6","volume":"22","author":"DH Mvunta","year":"2022","unstructured":"Mvunta\u00a0DH et\u00a0al (2022) Quality of life among cervical cancer patients following completion of chemoradiotherapy at Ocean Road Cancer Institute (ORCI) in Tanzania. BMC Womens Health 22:426. https:\/\/doi.org\/10.1186\/s12905-022-02003-6","journal-title":"BMC Womens Health"},{"issue":"04","key":"2196_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1055\/s-0039-1683355","volume":"41","author":"LN Dos Santos","year":"2019","unstructured":"Dos Santos\u00a0LN et\u00a0al (2019) Health-related quality of life in women with cervical cancer. Rev Bras Ginecol Obstet 41(04):242\u2013248. https:\/\/doi.org\/10.1055\/s-0039-1683355","journal-title":"Rev Bras Ginecol Obstet"},{"key":"2196_CR17","doi-asserted-by":"publisher","first-page":"109501","DOI":"10.1016\/j.radonc.2023.109501","volume":"181","author":"S Spampinato","year":"2023","unstructured":"Spampinato\u00a0S et\u00a0al (2023) Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors. Radiother Oncol 181:109501. https:\/\/doi.org\/10.1016\/j.radonc.2023.109501","journal-title":"Radiother Oncol"},{"key":"2196_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-001134","author":"F Nunes de Arruda","year":"2020","unstructured":"Nunes de Arruda\u00a0F et\u00a0al (2020) Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a\u00a0randomized phase\u00a0II trial. Int J Gynecol Cancer. https:\/\/doi.org\/10.1136\/ijgc-2019-001134","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"2196_CR19","first-page":"3095","volume":"17","author":"N Dahiya","year":"2016","unstructured":"Dahiya\u00a0N et\u00a0al (2016) Quality of life of patients with advanced cervical cancer before and after chemoradiotherapy. Asian Pac J Cancer Prev 17(7):3095\u20133099","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"2196_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00066-022-02007-z","volume":"199","author":"JM Herter","year":"2023","unstructured":"Herter\u00a0JM et\u00a0al (2023) Influence of chemoradiation on the immune microenvironment of cervical cancer patients. Strahlenther Onkol 199(2):121\u2013130. https:\/\/doi.org\/10.1007\/s00066-022-02007-z","journal-title":"Strahlenther Onkol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02196-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T10:02:25Z","timestamp":1721901745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02196-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2196"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02196-1","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"3 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Alfrink, T.\u00a0Aigner, H.\u00a0Zoche, L.\u00a0Distel, and G.G.\u00a0Grabenbauer declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}